ArticleMolecular cytogenetics2026
Prenatal diagnosis and follow-up of a child with mosaic tetrasomy 9p without obvious abnormal clinical manifestations.
Article in Molecular cytogenetics, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
9 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionTo report the prenatal diagnosis and follow-up of a fetus with mosaic tetrasomy 9p without obvious abnormal clinical manifestations. CASE REPORT: A fetus diagnosed with mosaic T9p at Shaoxing Maternal and Child Health Hospital in February 2022 was selected as the study subject. The amniotic fluid karyotype was 47,XY,+i(9)(p10)[3]/46,XY[97]. CNV-seq revealed a 70.56 Mb copy number gain in 9p24.3q21.11 (mosaicism at 6%). After genetic counseling, the parents opted to continue the pregnancy. A 3.9 kg male fetus was delivered at full term with normal physical findings at birth. The baby was phenotypically normal and had normal psychomotor and language development at 3 years old, at our last postnatal follow-up. When the child was 3 years old, his physical measurement parameters (height: 97 cm; weight: 14 kg) and neurodevelopment milestones all met the age standards. His peripheral blood karyotype was 47,XY,+i(9)(p10)[10]/46,XY[90], with CNV-seq analysis indicating a 39.16 Mb copy number gain in the 9p24.3p13.1 region (mosaicism at 53%). This discrepancy with the amniotic fluid CNV-seq results was attributed to differences in segmentation algorithms or software. FISH detected T9p mosaicism in oral mucosa (11.2%) and urinary sediment cells (12.7%). A synthesis of data from karyotype analysis, CNV-seq, and FISH collectively substantiates the presence of an acquired alteration within the 9p region, while the evidence does not support the extension of this fragment across the centromere of chromosome 9 into the q arm.
conclusionThe combined use of various methods may be capable of more accurately determining break-points and mosaic levels of T9p during prenatal diagnosis. This enriches the clinical spectrum of T9p mosaicism and provides a basis for prenatal diagnosis and genetic counseling of children with this type of chromosome variation.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.